This is an illustrative scenario for a Turkish skincare brand, not a verified FDABridge client outcome. Imagine a moisturizer intended for US sale with an SPF 15 sun-protection claim. The claim changes its US regulatory analysis before registration or shipment; a country of origin or a cosmetic description elsewhere does not settle its FDA status.
FDA explains that moisturizers and makeup with SPF can be both cosmetics and drugs. The drug requirements apply because of the sun-protection intended use, while cosmetic requirements can still apply to the cosmetic function. The product is not automatically an unapproved drug merely because it carries SPF: the formulation, claims and route must be assessed. https://www.fda.gov/cosmetics/resources-consumers-cosmetics/cosmetics-safety-qa-personal-care-products
Check the sunscreen route first
For a monograph sunscreen, check current OTC Monograph M020 and applicable general OTC requirements, including active ingredients, testing, labeling and Drug Facts. The old 21 CFR Part 352 text alone is not a complete current route description. A product outside a lawful monograph route may need an approved application or a changed formulation and claims before marketing. Removing an SPF claim without assessing the actual formula and intended use does not automatically make a product a compliant cosmetic. https://www.fda.gov/drugs/understanding-over-counter-medicines/questions-and-answers-fdas-regulatory-actions-over-counter-sunscreen
If the product is marketed as a drug in the US, determine the responsible establishment roles, registration and listing duties, NDC labeler code and the label that matches the actual product. A listing or NDC number does not mean FDA approved it. Product approval, a monograph marketing route, drug establishment registration and cosmetic MoCRA obligations are different questions. https://www.fda.gov/drugs/development-approval-process-drugs/national-drug-code-database-background-information
The fee question follows the actual facility
OMUFA facility fees can apply to a qualifying owner of an OTC monograph drug facility; they are not an annual GDUFA charge for every SPF brand or every registered drug establishment. For FY2027, FDA identifies the January 1–September 30, 2026 fee-liable period, $47,891 MDF and $31,927 CMO government rates, and specific exclusions. Approved-application products and other fee programmes need their own analysis. A missing invoice is not proof of exemption, and the US Agent is not automatically the fee payer. https://www.fda.gov/industry/fda-user-fee-programs/over-counter-monograph-drug-user-fee-program-omufa
A practical decision for the brand
Map each proposed US SKU by intended use and actual formula. For the SPF moisturizer, confirm the drug and cosmetic duties, the lawful sunscreen route and the sites involved. If the brand considers a US version without sun-protection claims, reassess its formula, marketing and cosmetic filings before assuming a category change. Record the responsible entity, label and fee decision for each path. This scenario does not report a client's SKU count, filings, savings or FDA result.
FDABridge can scope its existing cosmetics and drug registration and listing services, with agent coordination where applicable to the agreed scope after the product route is identified. Ask about the professional quote and deliverables before work begins: https://fdabridge.com/cosmetics , https://fdabridge.com/drug and https://fdabridge.com/contact . No filing or consultation guarantees FDA acceptance or border admission.